Eli Lilly | LLY - Despesas De Vendas E Administração





Despesas De Vendas E Administração Alterar Data
AbbVie USD 3.84B 205M 2026-09
Abbott USD 4.27B 669M 2026-09
ALKERMES USD 190.54M 6.1M 2026-09
Amgen USD 1.68B 40M 2026-09
AstraZeneca USD 4.07B 1.73B 2026-09
Baxter International USD 730M 5M 2026-09
Biogen USD 752M 42.3M 2026-09
Bristol-Myers Squibb USD 1.7B 127M 2026-09
Coherus Biosciences USD 15M 6.26M 2025-12
Drreddys Laboratories INR 28.08B 13.61B 2026-09
Eli Lilly USD 3.12B 305M 2026-09
Gilead Sciences USD 1.52B 70M 2026-06
GlaxoSmithKline GBP 2.16B 39M 2026-09
Glaxosmithkline GBP 2.38B 264M 2026-09
J&J USD 6.25B 168M 2026-09
Medtronic 3.2B 141M 2026-06
Merck USD 2.86B 25M 2026-09
Neurocrine Biosciences USD 366.3M 16.8M 2026-09
Novartis USD 3.08B 163M 2026-09
Novartis USD 3.08B 58M 2026-09
Novo Nordisk DKK 16.31B 3.09B 2026-06
Perrigo USD 271.7M 3.01B 2026-09
Pfizer USD 3.28B 132M 2026-09
Phibro Animal Health USD 78.32M 10.24M 2025-12
Prestige Brands USD 2.08B 2.04B 2026-09
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sanofi EUR 2.31B 325M 2026-09
Sanofi EUR 2.63B 140M 2026-06
United Therapeutics USD 184.1M 22.6M 2026-09
Zoetis USD 582M 10M 2026-09